Sentences with phrase «advanced stage lung cancer»

Sadly, the x-ray clearly showed that he had advanced stage lung cancer.

In 1997, my grandmother was diagnosed with advanced stage lung cancer.

Management of malignant pleural effusion by suicide gene therapy in advanced stage lung cancer: a case series and literature review.

Not exact matches

Radiologists came from across the hospital to peer at the results, disbelieving: A perfectly healthy 21 - year - old nonsmoker with no family history of the disease had lung cancer, which three days later would be diagnosed as stage IV, the most advanced form.

In addition, the study showed that the 5 - year survival rate for selected older patients with advanced lung cancer who were treated with surgical therapy was 29.9 % for Stage III and 26.7 % for Stage IV.

Nivolumab is PD - 1 inhibitor, which is used to treat several cancers in their advanced stages, including melanoma, non-small cell lung cancer and kidney cancer.

«Some had failed multiple lines of treatment and were very, very sick, with advanced - stage lung cancer,» Shaw says.

The Lung Cancer Mutation Consortium at the University of Colorado Cancer Center reports this week in the journal Cancer that 24 of 920 patients (3 percent) with advanced - stage lung cancer had mutations in the gene HLung Cancer Mutation Consortium at the University of Colorado Cancer Center reports this week in the journal Cancer that 24 of 920 patients (3 percent) with advanced - stage lung cancer had mutations in the geneCancer Mutation Consortium at the University of Colorado Cancer Center reports this week in the journal Cancer that 24 of 920 patients (3 percent) with advanced - stage lung cancer had mutations in the geneCancer Center reports this week in the journal Cancer that 24 of 920 patients (3 percent) with advanced - stage lung cancer had mutations in the geneCancer that 24 of 920 patients (3 percent) with advanced - stage lung cancer had mutations in the gene Hlung cancer had mutations in the genecancer had mutations in the gene HER2.

«Our results suggest that administering p38 inhibitors to certain patients with advanced stages of colon cancer or with established metastases could be counterproductive and may enhance cell acquisition of lung colonization potential,» says Gomis.

ARandomized, Phase III, Double - Blind Placebo - Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progressing Patients following an Initial Four Cycles of Platinum - Based Combination Chemotherapy in Advanced, Stage IIIB / IV Non-Small Cell Lung Cancer

A Phase II Single - Arm Trial to Investigate Tepotinib in advanced (Stage IIIB / IV) Non-Small Cell Lung Cancer with MET Exon 14 (METex14) Skipping Alterations After Failure of at Least One Prior Active Therapy, Including a Platinum - Doublet - Containing Regimen

For more information regarding Bristol - Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: • Early stage IB - IIIA, operable non-small cell lung cancer, confirmed in tissue • Lung function capacity capable of tolerating the proposed lung surgery • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 1 • Available tissue of primary lung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could alung cancer, confirmed in tissue • Lung function capacity capable of tolerating the proposed lung surgery • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 1 • Available tissue of primary lung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could aLung function capacity capable of tolerating the proposed lung surgery • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 1 • Available tissue of primary lung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could alung surgery • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 1 • Available tissue of primary lung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could alung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could apply

DENVER — Capturing and summarizing the remarkable progress in lung cancer prevention, diagnosis, staging, and treatment in 2015, the International Association for the Study of Lung Cancer (IASLC) announces the inaugural publication of «Scientific Advances in Lung Cancer 2015» in the May 2016 issue of the IASLC's Journal of Thoracic Oncology (Jlung cancer prevention, diagnosis, staging, and treatment in 2015, the International Association for the Study of Lung Cancer (IASLC) announces the inaugural publication of «Scientific Advances in Lung Cancer 2015» in the May 2016 issue of the IASLC's Journal of Thoracic Oncology cancer prevention, diagnosis, staging, and treatment in 2015, the International Association for the Study of Lung Cancer (IASLC) announces the inaugural publication of «Scientific Advances in Lung Cancer 2015» in the May 2016 issue of the IASLC's Journal of Thoracic Oncology (JLung Cancer (IASLC) announces the inaugural publication of «Scientific Advances in Lung Cancer 2015» in the May 2016 issue of the IASLC's Journal of Thoracic Oncology Cancer (IASLC) announces the inaugural publication of «Scientific Advances in Lung Cancer 2015» in the May 2016 issue of the IASLC's Journal of Thoracic Oncology (JLung Cancer 2015» in the May 2016 issue of the IASLC's Journal of Thoracic Oncology Cancer 2015» in the May 2016 issue of the IASLC's Journal of Thoracic Oncology (JTO).

Inclusion Criteria: • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 • Have histologically or cytologically confirmed advanced or metastatic non-small cell lung cancer (NSCLC)(Stage IIIb or greater) • Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 • Known PD - L1 tumor status as determined by an immunohistochemistry (IHC) assay performed by the central laboratory on tissue obtained at Screening • A woman of childbearing potential must have a negative highly sensitive serum (beta - human chorionic gonadotropin [beta - hCG]-RRB- at Screening within 14 days prior to study drug administration Inclusion Criteria for Crossover: • Participants must have been randomized to Arm A of the study and had radiographic disease progression according to RECIST 1.1 • Participants must have a mandatory biopsy at the time of disease progression according to RECIST 1.1 prior to crossing over.

Lung cancer is the leading cause of cancer mortality worldwide, suffering from a late stage of disease at the time of diagnosis and a paucity of effective therapeutic strategies to treat advanced tumours.

According to the company, «More than 90 - percent of people diagnosed with lung cancer do not survive, in part because it is often found at an advanced stage.»